Caris Life Sciences shares ended trading at $28 per share on Wednesday, marking a 33% increase from its initial public offering (IPO) price of $21 per share.
The AI TechBio and precision medicine company was founded in 2008 based on the hypothesis that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients.
Caris’ triumphant IPO is a rare positive for the biotech sector. It is the only company involved in drug development that has gone public this quarter.
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze